姜黄素对雄激素依赖性前列腺癌细胞的诱导凋亡作用  

Curcumin-induced Apoptosis in Androgen-dependent Prostate Cancer Cell Line LNCaP in vitro

作　　者：郭辉[1] 余建华[2] 谌科[1] 叶章群[1] 刘国昌[3] 

机构地区：[1]华中科技大学同济医学院附属同济医院泌尿外科,湖北武汉430030 [2]武警湖北省总队医院泌尿外科,湖北武汉430061 [3]华中科技大学同济医学院附属同济医院小儿外科,湖北武汉430030

出　　处：《中华男科学杂志》2006年第2期141-144,共4页National Journal of Andrology

摘　　要：目的:探讨姜黄素对雄激素依赖性前列腺癌细胞株(LNCaP)的诱导凋亡作用。方法:分别用10、25、50、75、100μmol/L浓度的姜黄素作用于LNCaP细胞,5、12、24 h后MTT法检测细胞生长活性;24 h后流式细胞仪测定细胞周期及细胞凋亡的变化,透射电镜观察细胞超微结构变化;5 h后W estern印迹法检测细胞内IκBα的表达。结果:姜黄素能显著抑制LNCaP细胞的生长,呈剂量与时间依赖性,不同浓度姜黄素组之间与不同作用时间组之间的差异均有显著性意义(P均<0.05)。姜黄素诱导LNCaP细胞出现剂量依赖性G2/M期阻滞(P<0.01),各浓度组凋亡细胞比例均显著高于空白对照组(P均<0.05),差异有显著性意义;姜黄素作用24 h后LNCaP细胞出现凋亡的形态学改变;不同浓度姜黄素作用后,LNCaP细胞内IκBα的表达无变化。结论:姜黄素能显著抑制LNCaP细胞的体外生长,并促进其凋亡。Objective： To explore the apoptosis induction by curcumin in androgen-dependent prostate cancer cell line （LNCaP）. Methods： After LNCaP cells were induced by 10, 25, 50, 75, 100μmol/L curcumin respectively, the cell activity was assayed by MTT at 5, 12 and 24 hours. Flow cytometry and electronic microscopy were adopted to observe cell cycle and morphological changes of LNCaP cells at 24 hours. After 5 hours, the expression of IKBα in LNCaP cells was detected by Western blotting. Results ： The growth of LNCaP cells was suppressed obviously by curcumin in dose-dependent and time-dependent manners in vitro. There were significant differences in inhibition rate among different concentrations and time groups （ P 〈 0.05 ）. Furthermore, cureumin could arrest the cell cycle of LNCaP cells at G2/M phase in a dose-dependent manner （ P 〈 0.01 ）. The ratios of apoptosis were significantly higher than those of controls （ P 〈 0.05 ）. Curcumin could lead to characteristic morphological changes of apoptosis in LNCaP cells after 24 hours. The expression of IKBα in LNCaP cell did not show marked changes after the exposure to different concentrations of curcumin within 5 hours. Conclusion ： Curcumin can suppress the growth of LNCaP, and promotes their apoptosis.

关 键 词：前列腺癌 姜黄素 细胞株 LNCaP 凋亡 体外研究 

分 类 号：R737.25[医药卫生—肿瘤] R979.1[医药卫生—临床医学]